Literature DB >> 2319642

Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals.

J Homsy1, M Meyer, J A Levy.   

Abstract

The sera from 16 individuals infected with the human immunodeficiency virus (HIV) at different clinical stages were evaluated for antibody-dependent neutralization and/or enhancement of infectivity by HIV. The HIV isolate from each individual (homotypic) and established laboratory strains showing broad cellular host range and cytopathicity were used. All sera could neutralize one of the laboratory-passaged isolates, whereas only two could neutralize the corresponding homotypic strain. Seven homotypic isolates were enhanced by serum from the respective individual. This activity was primarily observed in patients with acquired immune deficiency syndrome. Moreover, the tropism for macrophages of four of these seven viral isolates was found to be enhanced by the homotypic sera. Finally, sequential pairs of HIV and sera obtained from five HIV-infected individuals with different clinical progression were studied over time. The enhancing activity of three of the five sera appeared to increase over time, indicating changes in both the host virus population and the type of antibodies produced. These results suggest that enhancing antibodies contribute to the spread and pathogenesis of HIV in vivo. They emphasize the necessity of studying further the association of enhancing antibodies and disease progression in infected individuals.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2319642      PMCID: PMC249276     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Recovery of AIDS-associated retroviruses from patients with AIDS or AIDS-related conditions and from clinically healthy individuals.

Authors:  J A Levy; J Shimabukuro
Journal:  J Infect Dis       Date:  1985-10       Impact factor: 5.226

2.  Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes.

Authors:  B H Hahn; M A Gonda; G M Shaw; M Popovic; J A Hoxie; R C Gallo; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

3.  Persistent noncytopathic infection of normal human T lymphocytes with AIDS-associated retrovirus.

Authors:  J A Hoxie; B S Haggarty; J L Rackowski; N Pillsbury; J A Levy
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

4.  Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency.

Authors:  T Folks; D M Powell; M M Lightfoote; S Benn; M A Martin; A S Fauci
Journal:  Science       Date:  1986-02-07       Impact factor: 47.728

Review 5.  Pathogenesis of lentivirus infections.

Authors:  A T Haase
Journal:  Nature       Date:  1986 Jul 10-16       Impact factor: 49.962

6.  The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells.

Authors:  J Homsy; M Meyer; M Tateno; S Clarkson; J A Levy
Journal:  Science       Date:  1989-06-16       Impact factor: 47.728

7.  Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule.

Authors:  J S McDougal; M S Kennedy; J M Sligh; S P Cort; A Mawle; J K Nicholson
Journal:  Science       Date:  1986-01-24       Impact factor: 47.728

8.  AIDS retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen.

Authors:  J D Lifson; G R Reyes; M S McGrath; B S Stein; E G Engleman
Journal:  Science       Date:  1986-05-30       Impact factor: 47.728

9.  Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes.

Authors:  D Klatzmann; F Barré-Sinoussi; M T Nugeyre; C Danquet; E Vilmer; C Griscelli; F Brun-Veziret; C Rouzioux; J C Gluckman; J C Chermann
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

10.  Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions.

Authors:  A D Hoffman; B Banapour; J A Levy
Journal:  Virology       Date:  1985-12       Impact factor: 3.616

View more
  46 in total

1.  Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.

Authors:  W E Robinson; M K Gorny; J Y Xu; W M Mitchell; S Zolla-Pazner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

2.  Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Authors:  Erin Mehlhop; Camilo Ansarah-Sobrinho; Syd Johnson; Michael Engle; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

Review 3.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

Review 4.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

Review 5.  The spread, treatment, and prevention of HIV-1: evolution of a global pandemic.

Authors:  Myron S Cohen; Nick Hellmann; Jay A Levy; Kevin DeCock; Joep Lange
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

Review 6.  Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infection.

Authors:  J L Fahey
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

Review 7.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

8.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

9.  Enhanced in vitro human immunodeficiency virus type 1 replication in B cells expressing surface antibody to the TM Env protein.

Authors:  Y Tani; E Donoghue; S Sharpe; E Boone; H C Lane; S Zolla-Pazner; D I Cohen
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system.

Authors:  F Baldinotti; D Matteucci; P Mazzetti; C Giannelli; P Bandecchi; F Tozzini; M Bendinelli
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.